Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$6.5MCash on Hand
16.9mo Cash Runway
Follow VRAX by emailGet an email when VRAX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about VRAX, unsubscribe in one click. Privacy
📣 What VRAX Says Is Next
Q4 2026 · “Virax is preparing for its next major development milestone: a larger clinical validation analysis involving previously collected samples from 300 additional participants, with analysis expected to begin in Q4 2026 and results expected in Q1 2027.”
Company press release, May 26, 2026 · SEC filing
first half of 2028 · “Virax intends to use the net proceeds from the offering for general working capital needs, expecting to extend the Company’s cash runway into the first half of 2028, which is beyond planned completion of the US based post-acute sequelae of COVID-19 (“PASC”, or long COVID) study for submission to the FDA, as well as completion of the UK studies in post-acute infection syndrome (PAIS) for submission to the MHRA.”
Company press release, Dec 4, 2025 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Shareholder vote Virax called an extraordinary general meeting for November 27, 2026 to vote on a 1-for-4 reverse share consolidation effective December 14, 2026 or a later date accepted by Nasdaq. Shareholders will also vote on increasing authorized shares from 125,000,000 to 500,000,000 and adopting amended articles. Form 6-K · SEC filing · Press release
Oct 29, 2026 ·
Deal Virax Biolabs said its China subsidiary signed non-exclusive distribution agreements with AmyJet Scientific, Jiangsu Real-Gen Biotechnology and Zhixi (Shanghai) Biotechnology for its ImmuneSelect research-use products across six mainland Chinese markets. The filing gives no deal payments or sales targets. Form 6-K · SEC filing · Press release
Sep 10, 2026 ·
Financing Registers resale of up to 1,682,360 ordinary shares underlying warrants issued under a July 9, 2026 inducement letter and placement agent warrants. Series A and B warrant exercise price is $6.00, placement agent warrant price is $7.50. Form 424B3 · SEC filing
Sep 4, 2026 ·
Financing Virax Biolabs filed to update its at-the-market offering. It may now sell up to $2,070,060.20 of ordinary shares through H.C. Wainwright, excluding about $3,658,152 already sold under earlier supplements. Public float is $8,421,181. Form 424B5 · SEC filing
Sep 4, 2026 ·
Financing Virax amended its at-the-market sales agreement with H.C. Wainwright to raise the maximum offering amount of ordinary shares to up to $2,070,060.20, excluding $3,658,152 previously sold under the agreement. Form 6-K · SEC filing
Aug 26, 2026 ·
Shareholder vote Virax's August 21, 2026 adjourned extraordinary meeting approved a share capital increase from 2,000,000 to 500,000,000 ordinary shares. A proposed fifth amended memorandum and articles tied to a share consolidation was not approved. Form 6-K · SEC filing
Aug 18, 2026 ·
Virax Biolabs published an updated Q3 2026 investor presentation on its investor relations website. The filing itself contains no financial figures, trial data or other substantive disclosures. Form 6-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
VRAX holds $6.5M in cash and short-term investments and burns about $1.2M/quarter from operations,
an estimated runway of 16.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:58 · Elevated
Cash runway 17 months +18
ATM program on file since Sep 2026 +15
Shelf registration (F-3, Dec 2023) +10
Going-concern doubt in the latest 20-F +15As discussed in Note 1 to the consolidated financial statements, the Company’s significant operating losses raise substantial doubt about its ability to continue as a going concern.20-F, Jul 2026
Share count 579,218 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full VRAX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VRAX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.